中国综合临床
中國綜閤臨床
중국종합림상
CLINICAL MEDICINE OF CHINA
2015年
5期
401-403
,共3页
郑磊%熊子波%王青%罗琼%熊祖应
鄭磊%熊子波%王青%囉瓊%熊祖應
정뢰%웅자파%왕청%라경%웅조응
静脉注射%右旋糖酐铁%腹膜透析%肾性贫血
靜脈註射%右鏇糖酐鐵%腹膜透析%腎性貧血
정맥주사%우선당항철%복막투석%신성빈혈
Intravenously%Lron dextran%Peritoneal dialysis%Renal Anemia
目的 探讨静脉注射右旋糖酐铁治疗腹膜透析肾性贫血患者的临床效果.方法 选取2010年1月至2014年6月我院治疗的50例腹膜透析肾性贫血患者,随机分为对照组与观察组,每组各25例.观察组应用静脉注射右旋糖酐铁治疗,100 mg/次,3次/周;对照组使用琥珀酸亚铁200 mg/次,口服,3次/d.两组患者均需连续用药8周.对两组患者临床症状的变化以及治疗效果进行对比分析.结果 两组患者治疗8周血红蛋白、红细胞计数、红细胞比体积、网织红细胞计数、总铁结合力、血清铁均显著优于治疗前(P＜0.05或P＜0.01);观察组治疗8周(91.6±13.8) g/L、(3.4±0.4)×109/L、0.31±0.04、(1.7±0.6)％、(38.9±6.7)％、(525.9±81.4) μg/L显著优于对照组[(79.6±13.9) g/L、(3.0±0.7)×109/L、0.27±0.06、(1.4±0.6)％、(28.1±8.4)％、(377.2±107.2) μg/L],差异有统计学意义(P均＜0.05).治疗8周观察组总有效率80％ (20/25);对照组总有效率76％(19/25);两者差异无统计学意义(x2 =4.364,P＞0.05).观察组不良反应发生率为4％(1/25),对照组为8％ (2/25),差异无统计学意义(x2=4.895,P＞0.05).结论 腹膜透析肾性贫血患者静脉注射右旋糖酐铁治疗,可有效地改善患者的临床症状,补充患者体内的铁剂量.
目的 探討靜脈註射右鏇糖酐鐵治療腹膜透析腎性貧血患者的臨床效果.方法 選取2010年1月至2014年6月我院治療的50例腹膜透析腎性貧血患者,隨機分為對照組與觀察組,每組各25例.觀察組應用靜脈註射右鏇糖酐鐵治療,100 mg/次,3次/週;對照組使用琥珀痠亞鐵200 mg/次,口服,3次/d.兩組患者均需連續用藥8週.對兩組患者臨床癥狀的變化以及治療效果進行對比分析.結果 兩組患者治療8週血紅蛋白、紅細胞計數、紅細胞比體積、網織紅細胞計數、總鐵結閤力、血清鐵均顯著優于治療前(P＜0.05或P＜0.01);觀察組治療8週(91.6±13.8) g/L、(3.4±0.4)×109/L、0.31±0.04、(1.7±0.6)％、(38.9±6.7)％、(525.9±81.4) μg/L顯著優于對照組[(79.6±13.9) g/L、(3.0±0.7)×109/L、0.27±0.06、(1.4±0.6)％、(28.1±8.4)％、(377.2±107.2) μg/L],差異有統計學意義(P均＜0.05).治療8週觀察組總有效率80％ (20/25);對照組總有效率76％(19/25);兩者差異無統計學意義(x2 =4.364,P＞0.05).觀察組不良反應髮生率為4％(1/25),對照組為8％ (2/25),差異無統計學意義(x2=4.895,P＞0.05).結論 腹膜透析腎性貧血患者靜脈註射右鏇糖酐鐵治療,可有效地改善患者的臨床癥狀,補充患者體內的鐵劑量.
목적 탐토정맥주사우선당항철치료복막투석신성빈혈환자적림상효과.방법 선취2010년1월지2014년6월아원치료적50례복막투석신성빈혈환자,수궤분위대조조여관찰조,매조각25례.관찰조응용정맥주사우선당항철치료,100 mg/차,3차/주;대조조사용호박산아철200 mg/차,구복,3차/d.량조환자균수련속용약8주.대량조환자림상증상적변화이급치료효과진행대비분석.결과 량조환자치료8주혈홍단백、홍세포계수、홍세포비체적、망직홍세포계수、총철결합력、혈청철균현저우우치료전(P＜0.05혹P＜0.01);관찰조치료8주(91.6±13.8) g/L、(3.4±0.4)×109/L、0.31±0.04、(1.7±0.6)％、(38.9±6.7)％、(525.9±81.4) μg/L현저우우대조조[(79.6±13.9) g/L、(3.0±0.7)×109/L、0.27±0.06、(1.4±0.6)％、(28.1±8.4)％、(377.2±107.2) μg/L],차이유통계학의의(P균＜0.05).치료8주관찰조총유효솔80％ (20/25);대조조총유효솔76％(19/25);량자차이무통계학의의(x2 =4.364,P＞0.05).관찰조불량반응발생솔위4％(1/25),대조조위8％ (2/25),차이무통계학의의(x2=4.895,P＞0.05).결론 복막투석신성빈혈환자정맥주사우선당항철치료,가유효지개선환자적림상증상,보충환자체내적철제량.
Objective To investigate the clinical effect of intravenous iron dextran peritoneal dialysis patients with renal anemia.Methods Fifty cases of peritoneal dialysis patients with renal anemia in the Shenzhen Hospital of Peking University from Jan.2010 to Jun.2014 were randomly divided into control group and the observation group,and 25 cases in each group.Patients in observation group were given intravenous iron dextran at dose of 100 mg/time,and 3 times/week.Patients in control group were given ferrous succinate at dose of 200 mg/times orally,and 3 times/day.Both treatment period was eight weeks.Changes in clinical symptoms and treatment of the two groups of patients were recorded.Results Ater eight weeks treatment,the levels of hemoglobin(Hb),red blood cell count (RBC),hematocrit (Hct),reticulocyte count (Ret),total iron binding capacity(TS) and serum iron(SF) in two groups were significantly better than before treatment (P＜0.05 or P ＜0.01).The levels of Hb,RBC,Hct,Ret,TS and SF in observation group after treatment were (91.6± 13.8) g/L,(3.4± 0.4) × 109/L,0.31 ± 0.04,(1.7 ± 0.6) ％,(38.9 ± 6.7) ％ and (525.9 ± 81.4) μg/L,significantly better than those of control group((79.6 ± 13.9) g/L,(3.0±0.7) × 109/L,0.27±0.06,(1.4 ±0.6) ％,(28.1 ±8.4)％ and (377.2 ± 107.2) μg/L),and the differences were statistically significant (P ＜0.05).Total effective rate of observation group were 80％(20/25) and 76％(19/25) in the control group.The difference was not statistically significant(x2 =4.364,P＞0.05).Adverse reactions in observed group was 4％ (1/25) and 8％ (2/25) in control group (x2 =4.895,P ＞ 0.05).Conclusion The therapy of intravenous iron dextran on peritoneal dialysis patients with renal anemia can effectively improve the clinical symptoms,and supply iron for the patient.
